VYNE Therapeutics Inc. (NASDAQ:VYNE) Director Patrick G. Lepore Purchases 15,000 Shares

VYNE Therapeutics Inc. (NASDAQ:VYNE) Director Patrick G. Lepore acquired 15,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were bought at an average price of $2.92 per share, for a total transaction of $43,800.00. Following the transaction, the director now owns 51,472 shares in the company, valued at approximately $150,298.24. This represents a 41.13 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

VYNE Therapeutics Stock Performance

VYNE stock opened at $2.70 on Friday. The firm has a market cap of $39.83 million, a P/E ratio of -3.14 and a beta of 1.30. The firm’s fifty day moving average is $2.96 and its 200 day moving average is $2.35. VYNE Therapeutics Inc. has a 52 week low of $1.57 and a 52 week high of $4.30.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP bought a new stake in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics accounts for 0.0% of Lynx1 Capital Management LP’s portfolio, making the stock its 17th biggest holding. Lynx1 Capital Management LP owned 0.11% of VYNE Therapeutics as of its most recent filing with the Securities and Exchange Commission. 83.78% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. BTIG Research began coverage on VYNE Therapeutics in a research report on Monday, November 18th. They set a “buy” rating and a $8.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $5.75 price objective on shares of VYNE Therapeutics in a report on Tuesday.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.